论文部分内容阅读
对于乙型慢性肝炎的治疗,除年轻且肝纤维化轻度病例外,均宜首选核酸类似物,其中新上市的恩替卡韦(ETV)抗病毒效果强而耐药性出现率低,对初治病例首选应用的可能性高。在乙型急性肝炎,日本原来不存在的基因A型感染显示显著增加态势。对于丙型慢性肝炎的治疗,采用peg-IFNα-2b+利巴韦林(RBV)联合疗法,对基因1b型高病毒量病例进行48周治疗、2b型高病毒量病例进行24周治疗,与常规治疗相比取得较高的显效率。在肝细胞癌的治疗上,对早期病例施以经皮射频消融术;对高度进行性病例宜采取储药盒(reservior)肝动脉注射化疗;肝储备功能低下病例可行肝移植等治疗方案。
For the treatment of chronic hepatitis B, except for young and mild cases of liver fibrosis are preferred nucleic acid analogues, including the newly listed entecavir (ETV) strong antiviral effect and low resistance rates, the initial treatment of cases High likelihood of preferred application. In type A acute hepatitis, the original non-existent gene type A in Japan showed a significant increase in the situation. For the treatment of chronic hepatitis C, peginterferon alfa-2b plus ribavirin (RBV) combination therapy was used to treat 48 weeks of high virulence gene type 1b and 24 weeks of treatment of high virulence type 2b for 24 weeks, Compared with the treatment of higher efficiency markedly. In the treatment of hepatocellular carcinoma, the early cases of percutaneous radiofrequency ablation; for advanced cases should take the reservoir (reservior) injection of hepatic artery chemotherapy; liver reserve dysfunction cases feasible liver transplantation and other treatment options.